Helixon offers an AI-driven platform that automates protein therapeutic discovery, covering target identification, sequence generation, and candidate optimization. By using large‑scale machine‑learning models to predict binding affinity, stability, and developability, the system narrows experimental space, speeds up R&D timelines, and reduces laboratory costs for pharma and biotech companies.
Funding
Funding not disclosed
Founders
Product
Problem
Developing protein therapeutics traditionally requires extensive experimental screening, long timelines, and high costs, which limit the speed at which new drugs can reach patients.
Solution
Helixon provides an AI-driven platform that automates key stages of protein therapeutic discovery, from target identification to candidate optimization. The system leverages large‑scale machine‑learning models trained on structural and functional protein data to predict binding affinity, stability, and developability. By generating and evaluating thousands of in‑silico designs, the platform narrows the experimental space to the most promising candidates, reducing laboratory workload and accelerating timelines. Integrated analytics and visualization tools enable researchers to track design iterations, assess risk, and make data‑driven decisions throughout the R&D workflow.
Target Audience
Primary customers are pharmaceutical companies and biotechnology firms seeking to accelerate protein‑based drug discovery and reduce experimental costs.
Features
- Generative AI models that propose novel protein sequences with desired functional properties
- Predictive algorithms for binding affinity, solubility, immunogenicity, and manufacturability
- End‑to‑end workflow integration linking target definition, design, in‑silico screening, and experimental validation
- Interactive dashboard for real‑time monitoring of design metrics and iteration history
- API and data export capabilities for seamless incorporation into existing biotech pipelines